Lyudmila Bazhenova, MD, Discusses the Reasoning Behind Testing for EGFR Exon 20 Insertions in NSCLC at 2021 WCLC

Video

CancerNetwork® sat down with Lyudmila Bazhenova, MD, at the 2021 World Conference on Lung Cancer to talk about immunotherapy response in patients with EGFR exon 20 insertion mutations.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Lyudmila Bazhenova, MD, of University of California at San Diego, about methods and objectives of a study that investigated response to immunotherapy in patients with EGFR exon 20 insertion mutant non–small cell lung cancer versus those with wild-type disease.

Transcript:

Patients with EGFR exon 20 insertion [mutations] are the third most prevalent class of EGFR mutant non–small cell lung cancer [and] those patients were excluded from the majority of the clinical trials. With immune checkpoint inhibitors, we really don’t know how those patients perform when given immunotherapy. We also don’t know how many of those patients receive immunotherapy in real life. Therefore, we used our flatiron database spanning the years of 2015 to 2020. The reason why we selected those years was because those were the years where immune checkpoint inhibitors became widely available and used in the community. This [analysis] separated the patients into the EGFR exon 20 insertion [mutant disease] cohort, and a wild-type non–small cell lung cancer cohort, which we defined [with an] EGFR-and ALK-negative test.

Reference

Bazhenova L, Girard N, Minchom A, et al. Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. Presented at: 2021 World Conference on Lung Cancer; September 8-14, 2021. Virtual. Abstract P08.04.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
4 experts in this video
4 experts in this video
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content